Population pharmacokinetics of onercept in healthy subjects

Clinical Pharmacokinetics

Volumn 44, Issue 12, 2005, Pages 1295-1304

  Glatt, Sophie ^a,b,c   Fuseau, Eliane ^a   Buraglio, Mauro ^b,d   Nguyen, Quyen T X ^b  

^a EMF Consulting   (France)

^b Serono International SA   (Switzerland)

^c ELI LILLY AND COMPANY   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONERCEPT;

ADULT; ARTICLE; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL MODEL;

ADOLESCENT; ADULT; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 29244441652     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544120-00008     Document Type: Article

References (27)

1. Lantz M, Gullberg U, Nilsson E, et al. Characterization in vitro of a human tumour necrosis factor-binding-protein: a soluble form of tumour necrosis factor receptor. J Clin Invest 1990; 86: 1396-402
2. Nikas S, Drosos A. Onercept serono. Curr Opin Investig Drugs 2003; 4 (11): 1369-76
3. Gascon MP, Porchet HC, Le Cotonnec JY, et al. Pharmacokinetics and tissue distribution of human urinary tumour necrosis factor binding protein in mice. Drug Metab Dispos 1992; 20: 592-5
4. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003; 49 (2 Suppl.): S112-7
5. Nahar IK, Shojania K, Marra CA, et al. Infliximab treatment for rheumatoid arthritis and Crohn's disease. Ann Pharmacother 2003; 37 (9): 1256-65
6. Van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumor necrosis factor alpha monoclonal antibody adalimulad (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003; 62 (12): 1168-77
7. Scheinfeld N. Adalimumab (HUMIRA): a review. J Drugs Dermatol 2003; 2 (4): 375-7
8. Culy CR, Keating GM. Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Biodrugs 2003; 17 (2): 139-45
9. Trinchard-Lugan I, Ho-Nguyen Q, Bilham WM, et al. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumor necrosis factor-binding protein-1 (onercept) in-jected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. Eur Cytokine Netw 2001; 12: 391-8
10. Reports of the studies IMP20099, IMP20299 and IMP23279. Data on file, Serono International S.A.
11. Sheiner LB, Rosenberg B, Marathe VV. Estimation of the population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445-79
12. Grasela TH, Sheiner LV. Pharmacostatistical modeling for observational data. J Pharmacokinet Biopharm 1991; 19: 25-36S
13. Buraglio M. Phase I study to assess the safety, the tolerability, the pharmacokinetics and the pharmacodynamics of r-hTBP-1 after single intravenous administration at increasing doses in 12 healthy male subjects (IMP20099). Cambridge: Bourn Hall Clinic, 1998
14. Buraglio M. A phase I study to assess and to compare the pharmacokinetics, the pharmacodynamics, the bioavailability and the safety of r-hTBP-1 following IV, IM and SC single-dose administration to healthy subjects (IMP20299). Cambridge: Bourn Hall Clinic, 1998
15. Febbaro S. A phase I, double-blind, placebo-controlled study to assess the safety of onercept, following repeated SC administrations in a small group of healthy male subjects (IMP23279). Merthyr Tydfil: Simbec Research Ltd, 2001
16. Walker MJ, Ythier A, Munafo A, et al. The influence of tumour necrosis factor alpha and TNF binding protein on their individual measurement in serum by immunoassay or bioassay [abstract]. J Interferon Cytokine Res 1999; 19: 172
17. Beal SL, Sheiner LB. NONMEM user's guide. San Francisco (CA): NONMEM Project Group, University of California, 1992
18. Cosson VF, Fuseau EM. Mixed effect modelling of sumatriptan: pharmacokinetics during development: II. From healthy subjects to phase 2 doses ranging in patients. J Pharmacokinet Biopharm 1999; 2: 149-71
19. Karlson MO, Beal SL, Sheiner LB. Three new residuals error models for population PK/PD analyses. J Pharmacokinet Biopharm 1995; 23: 651-72
20. Beal SL, Sheiner LB, editors. NONMEM users guide, part VII. San Francisco (CA): University of California, 1998
21. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21: 735-50
22. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20 (5): 511-28
23. Hogg R, Tanis E. Probability and statistical inference. New York: Macmillan, 1977: 393
24. Zar J. Biostatistical analysis. Englewood Cliffs (NJ): Prentice Hall, 1974: 54
25. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds fol-lowing subcutaneous administration. Pharm Res 1990; 7: 167-9
26. Radwanski E, Chakraborty A, Van wart S, et al. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res 1998; 12: 1895-901
27. Supersaxo A, Rubas W, Hartmann HR, et al. The antitumour effect of lipophilic derivatives of 5-fluoro-2′-deoxyuridine incorporated into liposomes. J Microencapsul 1998; 5 (1): 1-11